P1074: PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA

• Wenyan Yu,
• Mei Geng,
• Jie Hao,
• Zeying Yan,
• Jian-Qing MI

Affiliations

Wenyan Yu

1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Mei Geng

2 Department of Oncology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jie Hao

3 Department of Hematology, Shanghai North Station Hospital

Zeying Yan

4 Department of Hematology, Rui Jin North Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

Jian-Qing MI

5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine